About Ocular Therapeutix, Inc.
We are a biopharmaceutical company, founded in 2006, that formulates, develops, and commercializes therapies for eye diseases. We use our proprietary bioresorbable hydrogel-based formulation technology, ELUTYX™, to create drug delivery solutions that simplify existing treatments. Our work covers ocular drug delivery, surgical sealants, sustained delivery, and ophthalmic therapies for conditions like ophthalmology, optometry, retina, cataract, glaucoma, wet AMD, and anti-VEGF treatments. DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg is our commercially available product. It is FDA-approved for intracanalicular use to treat ocular inflammation and pain after ophthalmic surgery, and ocular itching from allergic conjunctivitis. We market DEXTENZA® directly through our sales force. Our lead clinical program is AXPAXLI™ (axitinib intravitreal implant, also known as OTX-TKI), which we are developing for wet AMD and diabetic retinopathy. Other clinical programs include PAXTRAVA™ (travoprost intracameral implant, also known as OTX-TIC) for elevated intraocular pressure in primary open-angle glaucoma or ocular hypertension, OTX-CSI (cyclosporine ophthalmic insert) for chronic dry eye disease, and OTX-DED (dexamethasone ophthalmic insert) for short-term dry eye disease. We also develop marketing strategies and patient education tools for Eye Care Professionals. Additionally, we manage quality risk management, clinical data management, and clinical quality assurance activities to support our pipeline.
Mission & Values
We foster a proactive, risk-based culture that prioritizes patient safety and product quality throughout every stage of our products’ development. We value diverse, equitable, and inclusive practices, and we take a solution-oriented approach to quality management and improvement.
Team & Culture
We are a company with 51-200 employees. Our work environment emphasizes strong cross-functional collaboration, internal teamwork, and engagement with external partners. We aim to build a quality culture across our clinical organization, supporting continuous improvement. Work arrangements vary; some roles are fully remote and US-based, while others are onsite with hybrid options, or offer flexibility between onsite and remote. Certain positions may require up to 25% or 40% travel.
Frequently Asked Questions
Ocular Therapeutix develops and commercializes innovative therapies for diseases and conditions of the eye, utilizing its proprietary ELUTYX™ bioresorbable hydrogel-based formulation technology. Its commercially available product is DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg, an FDA-approved corticosteroid for treating ocular inflammation and pain after ophthalmic surgery, and ocular itching associated with allergic conjunctivitis. The company also has clinical programs, including AXPAXLI™ for wet AMD and diabetic retinopathy, PAXTRAVA™ for elevated intraocular pressure, and OTX-CSI and OTX-DED for dry eye disease.
Ocular Therapeutix promotes a proactive, risk-based culture that prioritizes patient safety and product quality. It emphasizes strong cross-functional collaboration, teamwork across internal departments, and partnerships with external stakeholders. The company values diverse, equitable, and inclusive practices and maintains a solution-oriented approach to quality management and continuous improvement.
Ocular Therapeutix offers various work environments, including fully remote US-based roles for certain positions such as Executive Director of ECP Marketing and Manager of Clinical Data Management. Other roles, like the Quality Risk Management Manager, are primarily onsite with hybrid options. Some leadership positions provide flexibility for onsite or remote work. Travel requirements can vary by role, with some positions requiring up to 25% or 40% travel.
Ocular Therapeutix drives the strategy, implementation, and optimization of a Quality Risk Management (QRM) program that complies with ICH Q9(R1) guidelines, integrating it into the Quality Management System. The company conducts formal risk assessments, maintains a risk register, and provides QA oversight for GCP compliance across all clinical studies. This includes managing audits of service providers and sponsor trials, resolving audit findings and CAPAs, and supporting regulatory inspections.
Ocular Therapeutix, Inc. was founded in 2006.
Ocular Therapeutix, Inc. is active in the Ocular Drug Delivery, Surgical Sealants, Sustained Delivery, Ophthalmic Therapies, Ophthalmology, Optometry, Retina, Cataract, Glaucoma, Wet Amd, Anti-vegf, and Drug Delivery markets.
Ocular Therapeutix, Inc. has 51-200 employees.
Ocular Therapeutix, Inc. hires in 🇺🇸 United States.
Yes! Ocular Therapeutix, Inc. is actively hiring with 6 open remote jobs available now.
Yes, Ocular Therapeutix, Inc. is a remote-first company.
Ocular Therapeutix, Inc.'s website is www.ocutx.com .
You can find Ocular Therapeutix, Inc. on LinkedIn .
6 remote jobs at Ocular Therapeutix, Inc.
Explore latest remote opportunities and join a team that values work flexibility.
Medical and Scientific Publications Manager
Ocular Therapeutix, Inc.
Executive Director Eye Care Professional Marketing
Ocular Therapeutix, Inc.
Manager, Risk Management
Ocular Therapeutix, Inc.
Manager, Clinical Data Management
Ocular Therapeutix, Inc.
Senior Manager, Clinical Quality Assurance
Ocular Therapeutix, Inc.
Executive Director Clinical Quality Assurance
Ocular Therapeutix, Inc.
Remote companies like Ocular Therapeutix, Inc.
Find your next opportunity with companies that specialize in Ocular Drug Delivery, Surgical Sealants, Sustained Delivery, and Ophthalmic Therapies. Explore remote-first companies like Ocular Therapeutix, Inc. that prioritize flexible work and home-office freedom.
4D Molecular Therapeutics
Develops and commercializes gene therapeutic products for serious unmet medical conditions using a proprietary vector discovery platform.
Ascendis Pharma
A global biopharmaceutical company developing therapies for rare endocrine diseases and cancer using its TransCon technology platform.
Tarsus Pharmaceuticals, Inc.
Develops biopharmaceutical therapies, starting with eye care, for diseases with unmet medical needs.
Adverum Biotechnologies
A clinical-stage company developing gene therapies for prevalent ocular diseases
Immunovant
A clinical-stage immunology company developing targeted therapies for autoimmune diseases using anti-FcRn technology.
ReCode Therapeutics
Develops clinical-stage genetic medicines using its SORT LNP platform for targeted delivery of mRNA and gene correction therapeutics.
Project: Career Search
Rev. 2026.2
[ Remote Jobs ]
Direct Access
We source jobs directly from 21,000+ company career pages. No intermediaries.
Discover Hidden Jobs
Unique jobs you won't find on other job boards.
Advanced Filters
Filter by category, benefits, seniority, and more.
Priority Job Alerts
Get timely alerts for new job openings every day.
Manage Your Job Hunt
Save jobs you like and keep a simple list of your applications.